Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study

Background: Overweight and obesity are common in patients with psoriasis and are associated with increased disease severity and declined treatment response. Aims: ) with moderate to severe psoriasis. Materials and Methods: comprised 16 and 33 cases, respectively. Baseline demographics and clinical characteristics were recorded, and Psoriasis Area and Severity Index (PASI) scores, adverse events, and biochemical parameters were assessed at weeks 12, 16, and 24. Results: < 0.001, respectively). Conclusions: , Secukinumab demonstrated a faster onset of efficacy, while Guselkumab demonstrated significantly higher efficacy at week 24.